Showing 3831-3840 of 5621 results for "".
- AsclepiX Therapeutics Raises $10 Million to Advance Phase 1/2a Clinical Study of AXT107https://modernod.com/news/asclepix-therapeutics-raises-10-million-to-advance-phase-12a-clinical-study-of-axt107/2481749/AsclepiX Therapeutics announced that it has secured a $10 million Series A-3 financing to advance clinical development of its lead candidate, AXT107 (gersizangitide), in patients with wet AMD. “With the completion of this round, we are excited to embark into the next phase of
- Study Identifies How Diabetes Slows Healing in the Eyehttps://modernod.com/news/study-identifies-how-diabetes-slows-healing-in-the-eye/2481742/Investigators from Cedars-Sinai have provided new understanding of how diabetes delays wound healing in the eye, identifying for the first time two related disease-associated changes to the cornea, according to a company news release.
- RestoringVision Appoints of Three Directors to its Leadership Teamhttps://modernod.com/news/restoringvision-appoints-of-three-directors-to-its-leadership-team/2481739/Nonprofit RestoringVision announced the appointment of three directors to its leadership team to strengthen its impact in solving the global vision crisis. This follows a year of growth, in which RestoringVision expanded its reach by 48 percent in 2022. In 2023, the organization aims to reac
- Visiox Pharma Licenses Glaucoma Drug Omlonti from Santenhttps://modernod.com/news/visiox-pharma-licenses-glaucoma-drug-omlonti-from-santen/2481736/Visiox Pharma announced it has entered into a definitive agreement with Santen Pharmaceutical to license glaucoma drug Omlonti (omidenepag isopropyl ophthalmic solution 0.002%). Specific financial terms of the deal were not disclosed. Omlonti was approved by th
- Harrow Acquires US and Canadian Commercial Rights to Dry Eye Drug Vevye from Novaliqhttps://modernod.com/news/harrow-acquires-us-and-canadian-commercial-rights-to-vevye-cyclosporine-ophthalmic-solution-01-from-novaliq/2481734/Harrow has entered the prescription dry eye disease treatment business as it announced a deal to acquire the US and Canadian commercial rights to Vevye (cyclosporine ophthalmic solution 0.1%) from Novaliq. Under terms of the deal, Harrow will make an initi
- Lars Ederleh Named New CSO at Schwind Eye-Tech-Solutionshttps://modernod.com/news/lars-ederleh-named-new-cso-at-schwind-eye-tech-solutions/2481731/Schwind eye-tech-solutions has named Lars Ederleh as Chief Sales Officer (CSO), effective this month. Bringing more than 20 years of international experience in laser technology, Mr. Ederleh will be in charge of the company’s sales and marketing operations.
- Medical Consulting Group and Corcoran Consulting Group Finalize Merger Agreementhttps://modernod.com/news/medical-consulting-group-and-corcoran-consulting-group-finalize-merger-agreement/2481723/Medical Consulting Group (MCG) and Corcoran Consulting Group (CCG) have finalized their merger that was announced in April. Financial terms of the deal were not disclosed. MCG and CCG stated they believe this merger will enhance the ophthalmic community by providing
- Tenpoint Therapeutics Launches with Goal of Reversing Vision Loss Through Engineered Cell-Based Therapeuticshttps://modernod.com/news/tenpoint-therapeutics-launches-with-goal-of-reversing-vision-loss-through-engineered-cell-based-therapeutics-and-in-vivo-reprogramming/2481720/Tenpoint Therapeutics announced its launch with a $70 million Series A financing to develop its regenerative medicine platform to replace multiple cell types lost to inherited and age-related conditions. Tenpoint was established based on the work of its scientific founders from Mo
- Cognition Therapeutics Doses First Patient in MAGNIFY Study of Oral CT1812 for GA Secondary to Dry AMDhttps://modernod.com/news/cognition-therapeutics-announces-dosing-of-first-patient-in-magnify-study-of-oral-ct1812-for-ga-secondary-to-dry-amd/2481714/Cognition Therapeutics announced that it has dosed the first participant in the phase 2 MAGNIFY study of CT1812, an experimental therapy being developed for the treatment of geographic atrophy (GA) secondary to dry age-related macular degeneration (AMD). The MAGNIFY study (COG2201,
- Nicox Estimates Potential Annual Global Net Sales for NCX 470 of Over $300 Millionhttps://modernod.com/news/nicox-estimates-potential-annual-global-net-sales-for-ncx-470-of-over-300-million/2481712/Nicox SA said it that annual global net sales of NCX 470 could be over $300 million within 8 years of the date of launches in the U.S. and China. The estimate was based on a US market survey evaluating the commercial potential of NCX 470, a nitric oxide (NO)-donating bima